Dostarlimab before colon surgery for mismatch-repair–deficient cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can follow study instructions (or have a legal representative sign if mild cognitive issues).
- Your colon cancer is stage II or III and confirmed mismatch-repair deficient (dMMR) on biopsy tissue.
- Your tumor can be removed by standard surgery, unless the study team says it can be skipped based on outcomes.
- Scans within 28 days show no spread (no metastasis) to other parts of the body.
- Your blood counts and organ labs meet minimum levels (white blood cells, platelets, hemoglobin, kidney and liver tests).
- You can safely take the study medicine: no recent major surgery, no serious active infections/unstable heart problems, and no recent strong immune-suppressing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can shrink or eliminate colon tumors in people with dMMR/MSI-high cancer, possibly allowing some to avoid surgery. It is for patients whose cancer has not spread.
This study tests giving an immunotherapy drug (pembrolizumab) before surgery for people with early-stage colon cancer that has a specific genetic feature. The goal is to see if the drug can shrink the tumor enough to avoid more extensive surgery.
This trial tests an investigational immunotherapy drug called dostarlimab given before surgery for colon cancer. It is for people whose tumor is MMR-proficient (also called MSS) and is large enough or has spread to nearby lymph nodes but not to other parts of the body. The goal is to see if this treatment can shrink the tumor before surgery.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This study tests how long treatment with a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) should continue in people with a certain type of rectal cancer. The goal is to see if treatment can be shortened based on how well the tumor responds, which may mean fewer side effects and a quicker recovery.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.